The move they made is a big cut," SlateStone Wealth's Kenny Polcari told CNBC's " Street Signs Asia " on Sept. 19.
Calling it a "crisis level cut," he added that "people [are] scratching their heads, going, what's it really mean?"
Federal Reserve Chair Jerome Powell stressed that the big rate cut does not signal that the risk of a recession is elevated.
According to FactSet data, of the 20 analysts covering the stock, 18 give it a buy or overweight rating, while two have a hold rating.
Biotech play Another stock Polcari is bullish on is biopharmaceutical player Amgen , given its pipeline of new products .
Persons:
Kenny Polcari, CNBC's, Jerome Powell, Polcari, Amgen, — CNBC's Sean Conlon
Organizations:
U.S, Biotech, U.S . Food, Drug Administration, Euronext, Nasdaq, Nvidia
Locations:
Federal, U.S, Amgen, Euronext Amsterdam, Dutch, ASML